Middle East and Africa Dry Eye Syndrome Market – Industry Trends and Forecast to 2030

Middle East and Africa Dry Eye Syndrome Market Analysis and Size

Ever-rising geriatric population base coupled with growing prevalence of deficiency of vitamin A is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing demand for better treatment options, rising awareness among population in regards to the early diagnosis, growing contribution of non-governmental organizations towards the disease and upsurge in the diagnosis rate are other factors also fostering the growth of the market. Increasing personal disposable income is other indirect determinant that will create lucrative market growth opportunities.

Data Bridge Market Research analyses that the Middle East and Africa dry eye syndrome market which was USD 6.61 billion in 2022, would rocket up to USD 10.78 billion by 2030, and is expected to undergo a CAGR of 6.5% during the forecast period. This indicates that the market value. “Adult” dominates the age segment of the Middle East and Africa dry eye syndrome market owing to rise in the aging population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Middle East and Africa Dry Eye Syndrome Market Scope and Segmentation

Market Definition

Dry eye syndrome is a medical condition wherein there is lack of moisture and lubrication in, around and on the surface of the eye. Medically known as keratoconjunctivitis sicca (KCS), dry eye syndrome is a commonly occurring disease and its symptoms include aching and burning sensations, sore eyes, red eyes, fatigued eyes, itchy eyes, and photophobia, among others.

Middle East and Africa Dry Eye Syndrome Market Dynamics

Drivers

• Ever Rising Geriatric Population

Ever rising geriatric population base coupled with growing prevalence of deficiency of vitamin A is a major factor fostering the growth of the market. Rising expenditure on the development of healthcare infrastructure, growing demand for better treatment options, rising awareness among population in regards to the early diagnosis, growing contribution of non-governmental organizations towards the disease and upsurge in the diagnosis rate are other factors also fostering the growth of the market.

• Rising Healthcare Infrastructure

Many countries in the MEA region have been investing in improving their healthcare infrastructure. This includes the expansion of eye care facilities and the training of healthcare professionals to diagnose and treat dry eye syndrome effectively.

Opportunity

• Tailored Treatment Approaches

The MEA region's diverse population and environmental factors require tailored approaches to dry eye syndrome treatment. Healthcare providers can explore custom treatment plans that take into account factors such as climate, patient demographics, and underlying medical conditions. Personalized medicine can lead to better outcomes and patient satisfaction.

Restraint/Challenge

• Regulatory Challenges

Regulatory approval processes for new pharmaceuticals and medical devices can be time-consuming and complex in some MEA countries. This can delay the introduction of innovative dry eye treatments to the market.

This Middle East and Africa dry eye syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa dry eye syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2021, in the years leading up to 2021, Novartis successfully obtained approvals for Xiidra (Lifitegrast) from regulatory authorities in various countries worldwide. These approvals included countries in the MEA region

Middle East and Africa Dry Eye Syndrome Market Scope

Middle East and Africa dry eye syndrome market is categorized into six notable segments which are based on the basis of type, product, disease, treatment, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Emulsions
• Lubricant Eye Drops/Solutions
• Eye Ointments
• Autologous Serum Eye Drops
• Nutrition Supplements
• Others

Product

• Cyclosporine
• Corticosteroids
• Lifitegrast,
• Ocular lubricant
• Punctual plug
• Others

Disease

• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome

Treatment

• Lubricating Agents
• Tear Stimulators
• Artificial Tears
• Anti-Inflammatory Drugs
• Antibiotic Drugs
• Others

End-User

• Home Healthcare
• Hospitals
• Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Middle East and Africa Dry Eye Syndrome Market Regional Analysis/Insights

The dry eye syndrome treatment market is analyzed and market size insights and trends are provided by type, product, disease, treatment, end-user and distribution channel as referenced above.

The countries covered in the dry eye syndrome treatment market report are South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

Saudi Arabia in Middle East and Africa region dominates the dry eye syndrome treatment market owing to the earliest adoption of advanced healthcare technologies, growing prevalence of eye-related disorders and significant increase in the geriatric population base.

The country section of the dry eye syndrome treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and up-stream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Dry Eye Syndrome Market Share Analysis

Middle East and Africa dry eye syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Middle East and Africa dry eye syndrome market.

Some of the major players operating in the Middle East and Africa dry eye syndrome market are:

• Mitotech, SA (Luxembourg)
• Hindawi Limited (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Otsuka Holdings Co., Ltd. (Japan)
• ALLERGAN (Ireland)
• Novaliq GmbH (Germany)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Prestige Consumer Healthcare, Inc. (U.S.)
• Horus Pharma (France)
• Senju Pharmaceutical Co. Ltd. (Japan)
• VISUfarma (U.K.)
• Akorn Operating Company LLC (U.S.)
• Bausch & Lomb Incorporated (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Alcon (Switzerland)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Novartis AG (Switzerland)
• Similasa (Switzerland)
• Scope Ophthalmics Ltd. (U.K.)

SKU-44908